Exploring Uncertainty in Cost-Effectiveness Analysis
暂无分享,去创建一个
[1] Andrew Briggs,et al. An Introduction to Markov Modelling for Economic Evaluation , 1998, PharmacoEconomics.
[2] M. Sculpher,et al. Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.
[3] A A Stinnett,et al. Net Health Benefits , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.
[4] C E Phelps,et al. On the (Near) Equivalence of Cost-Effectiveness and Cost-Benefit Analyses , 1991, International Journal of Technology Assessment in Health Care.
[5] John D. Graham,et al. Going beyond the single number: Using probabilistic risk assessment to improve risk management , 1996 .
[6] M D Stevenson,et al. Gaussian Process Modeling in Conjunction with Individual Patient Simulation Modeling: A Case Study Describing the Calculation of Cost-Effectiveness Ratios for the Treatment of Established Osteoporosis , 2004, Medical decision making : an international journal of the Society for Medical Decision Making.
[7] D J Nokes,et al. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. , 1999, Statistics in medicine.
[8] A E Ades,et al. Evidence synthesis, parameter correlation and probabilistic sensitivity analysis. , 2006, Health economics.
[9] Mark Sculpher,et al. Subgroups and Heterogeneity in Cost-Effectiveness Analysis , 2012, PharmacoEconomics.
[10] Karl Claxton,et al. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence , 2007, Journal of health services research & policy.
[11] John C. Hershey,et al. Carrier Screening for Cystic Fibrosis , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.
[12] W. H. Pun,et al. Statistical Decision Theory , 2014 .
[13] I. White,et al. Eliciting and using expert opinions about dropout bias in randomized controlled trials , 2007, Clinical trials.
[14] Mark J Sculpher,et al. Dangerous omissions: the consequences of ignoring decision uncertainty. , 2011, Health economics.
[15] Stephen Palmer,et al. The Half-Life of Truth: What Are Appropriate Time Horizons for Research Decisions? , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.
[16] Gordon B. Hazen,et al. Sensitivity Analysis and the Expected Value of Perfect Information , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.
[17] Mark Sculpher. NICE’s 2008 Methods Guide , 2012, PharmacoEconomics.
[18] Peter Littlejohns,et al. Making a decision to wait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of research. , 2007, Journal of the Royal Society of Medicine.
[19] Karl Claxton,et al. Probabilistic analysis and computationally expensive models: Necessary and required? , 2006, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[20] Nick Black,et al. The Cooksey review of UK health research funding , 2006, BMJ : British Medical Journal.
[21] Sarah Wordsworth,et al. Eliciting expert opinion for economic models: an applied example. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[22] James O. Berger. Statistical Decision Theory , 1980 .
[23] Andrew Briggs,et al. Value based pricing for NHS drugs: an opportunity not to be missed? , 2008, BMJ : British Medical Journal.
[24] Andrew Briggs,et al. Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions. , 2004, Health economics.
[25] M J Al,et al. Costs, effects and C/E-ratios alongside a clinical trial. , 1994, Health economics.
[26] Andrew R Willan,et al. Expected value of information and decision making in HTA. , 2007, Health economics.
[27] A E Ades,et al. Expected Value of Sample Information Calculations in Medical Decision Modeling , 2004, Medical decision making : an international journal of the Society for Medical Decision Making.
[28] Alex J. Sutton,et al. Multiparameter evidence synthesis in epidemiology and medical decision‐making: current approaches , 2006 .
[29] Karl Claxton,et al. Dimensions of Design Space: A Decision-Theoretic Approach to Optimal Research Design , 2009, Medical decision making : an international journal of the Society for Medical Decision Making.
[30] Julien Taieb,et al. Truth Survival in Clinical Research: An Evidence-Based Requiem? , 2002, Annals of Internal Medicine.
[31] Karl Claxton,et al. Defining and characterising structural uncertainty in decision analytic models , 2006 .
[32] Nicky J Welton,et al. Preventive strategies for group B streptococcal and other bacterial infections in early infancy: cost effectiveness and value of information analyses , 2007, BMJ : British Medical Journal.
[33] David Draper,et al. Assessment and Propagation of Model Uncertainty , 2011 .
[34] Keith Abrams,et al. Use of Indirect and Mixed Treatment Comparisons for Technology Assessment , 2012, PharmacoEconomics.
[35] K Claxton,et al. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. , 1999, Journal of health economics.
[36] Anthony O'Hagan,et al. Calculating Partial Expected Value of Perfect Information via Monte Carlo Sampling Algorithms , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.
[37] Jeremy E. Oakley,et al. Uncertain Judgements: Eliciting Experts' Probabilities , 2006 .
[38] Fumie Yokota,et al. Value of Information Literature Analysis: A Review of Applications in Health Risk Management , 2004, Medical decision making : an international journal of the Society for Medical Decision Making.
[39] C. Chatfield. Model uncertainty, data mining and statistical inference , 1995 .
[40] Zaid Chalabi,et al. Budgetary policies and available actions: a generalisation of decision rules for allocation and research decisions. , 2010, Journal of health economics.
[41] Matt Stevenson,et al. Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA. , 2007, Health economics.
[42] S. Palmer,et al. Incorporating option values into the economic evaluation of health care technologies. , 2000, Journal of health economics.
[43] Alan Brennan,et al. Expected value of sample information for Weibull survival data. , 2007, Health economics.
[44] M. Sculpher,et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. , 2005, Health economics.
[45] Simon Dixon,et al. Testing the Validity of Cost-Effectiveness Models , 2000, PharmacoEconomics.